Qelbree Side Effects in Adults, Teens, and Children

Qelbree (viloxazine extended-release) causes side effects in a majority of people who take it, though most are mild to moderate. The specific effects differ somewhat between children and adults, but the most frequently reported ones across age groups include nausea, headache, insomnia, fatigue, decreased appetite, and drowsiness. The medication also carries a boxed warning about suicidal thoughts in children and young adults, which tends to draw the most concern from patients and parents. Understanding how these side effects break down, how often they actually lead people to stop the drug, and what the longer-term picture looks like can help put the risk in perspective.

The Most Common Side Effects in Adults

In the pivotal phase III trial for adults, the side effects that showed up in at least one in ten participants receiving Qelbree were insomnia (about 15%), fatigue (roughly 12%), nausea (about 10%), and decreased appetite (about 10%). Dry mouth and headache each appeared in about 9% of participants.¹ A longer-term open-label extension study found similar patterns, with insomnia and nausea each affecting about 14% of adults, headache about 11%, and fatigue about 10%.²

A more recent phase 4 trial that enrolled adults who also had symptoms of depression or anxiety found a broader spread. About 71% of participants reported at least one side effect, but the majority were still mild or moderate. That trial added constipation, migraine, and somnolence to the list of common complaints beyond the usual nausea and insomnia.³ The higher rate likely reflects the fact that open-label trials without a placebo comparison tend to capture more reported events, and the patient population in that study may have been more vulnerable to mood-related side effects.

Side Effects in Children and Adolescents

The profile in younger patients looks a bit different. In adolescents, drowsiness (somnolence) was the most common treatment-related side effect at about 14%, followed by decreased appetite (about 7%), nausea (about 5%), and fatigue (about 5%).⁴ Across the pediatric clinical program more broadly, somnolence, decreased appetite, and headache were consistently the top three complaints.⁵

The practical takeaway is that kids on Qelbree tend to get sleepy more often than adults do, while adults are more likely to have trouble falling asleep. Both groups deal with nausea and appetite loss, but insomnia and dry mouth are disproportionately adult problems. Most side effects in the adolescent trials were rated as mild (about 30%) or moderate (about 17%), with only about 1.5% reporting anything severe.⁶

The Suicidal Ideation Warning

Like all medications approved for ADHD in younger patients, Qelbree carries a boxed warning about suicidal thoughts and behavior in children, adolescents, and young adults. This is the most prominent warning on the label and understandably causes alarm. A pharmacovigilance analysis of the FDA’s Adverse Event Reporting System found that suicidal ideation was among the most disproportionately reported psychiatric events for viloxazine, with a strong signal compared to what would be expected by chance.⁷

In the phase 4 adult trial, suicidal ideation led to discontinuation in three participants, and two of those cases were considered serious and related to the drug. Both occurred within the first three days of treatment.⁸ A separate real-world pharmacovigilance comparison found that the top psychiatric adverse events reported for viloxazine included anger, completed suicide, suicidal ideation, mood swings, and agitation.⁹

Context matters here. Reporting databases collect voluntary reports and cannot establish that the drug caused the event, only that the event happened during treatment. People with ADHD already have an elevated baseline risk for suicidal thoughts, and the boxed warning class applies broadly to nonstimulant ADHD drugs and antidepressants. That said, the signal is real enough that clinicians are advised to monitor closely, especially during the first weeks of treatment and any dose changes. If you or someone you know is starting Qelbree and notices new or worsening thoughts of self-harm, that warrants an immediate call to the prescriber.

How Often People Quit Because of Side Effects

One of the more useful numbers for understanding how tolerable a drug really is in practice is the discontinuation rate due to side effects. In the controlled adult trial, about 9% of people on Qelbree stopped because of adverse events, compared with about 5% on placebo.¹⁰ In the longer open-label extension, that number climbed to about 18%, with insomnia, nausea, and fatigue being the most common reasons for dropping out.¹¹ The jump in the extension study reflects the longer exposure time and the fact that people in open-label trials know they are getting the real drug.

Adolescents fared better. Only about 3% discontinued due to side effects in the placebo-controlled trial.¹² For comparison, one retrospective study found that about 36% of patients switched from atomoxetine (Strattera) to viloxazine had originally quit atomoxetine because of side effects, most commonly stomach problems, irritability, and fatigue. Only 4% of those who then tried viloxazine stopped it for side effects.¹³ This suggests that some patients who cannot tolerate other nonstimulants do fine on Qelbree, though the reverse is also possible.

Insomnia Versus Drowsiness

One of the confusing things about Qelbree is that it can make you sleepy or keep you awake, and sometimes both at different points. This is not as paradoxical as it sounds. The drug works primarily by blocking the reuptake of norepinephrine, which is an alerting neurotransmitter, but it also modulates serotonin activity. The balance of these effects varies by individual, by dose, and by time of day. In adults, insomnia is the dominant sleep complaint and the single most common reason people quit the drug.¹⁴ In children and teens, drowsiness is more common than insomnia.¹⁵

In practice, some prescribers adjust the timing of the dose based on which sleep effect shows up. If it causes drowsiness, taking it in the evening may help. If it causes insomnia, morning dosing is standard and adjusting bedtime routines may be recommended. These are practical workarounds that do not always solve the problem, but for many patients the sleep effects diminish after the first few weeks as the body adjusts.

Does Qelbree Affect Growth in Children?

Appetite suppression is a concern with almost any ADHD medication, and parents often worry about long-term effects on weight and height. The data on Qelbree here are reassuring, at least so far. In a long-term open-label extension study of children and adolescents, participants stayed within normal growth ranges according to CDC growth charts throughout the study period. Weight and height z-scores remained between normal bounds at all visits, and the average changes from baseline were small.¹⁶

Interim results from that same extension showed that at 12 months, weight-for-age z-scores had dipped slightly (a mean change of about −0.2) and height-for-age z-scores also dipped a tiny amount (about −0.14), but both remained well within the normal population range. The pattern held whether the researchers looked at boys versus girls or different age brackets.¹⁷ These numbers suggest that while Qelbree can decrease appetite, it does not appear to produce the kind of growth velocity slowdown that has been seen with some stimulant medications over comparable time frames.

How It Compares to Stimulants and Other Nonstimulants

A systematic review comparing side-effect patterns across all seven FDA-approved adult ADHD treatments found something counterintuitive: nonstimulant medications like Qelbree produced more types of side effects, but stimulant medications tended to produce higher rates of individual side effects. The overall discontinuation rates due to side effects did not differ meaningfully between the two classes.¹⁸ In other words, you might experience a wider variety of nuisance effects on Qelbree than on a stimulant, but the chance that any given effect would be severe enough to make you stop is roughly similar.

Compared to atomoxetine specifically, the data from patients who switched from one to the other suggests that Qelbree is better tolerated on balance. In a retrospective study, more than a third of patients had quit atomoxetine because of side effects like GI upset, irritability, and fatigue, while only a small fraction who then switched to viloxazine had to stop it.¹⁹ One area where Qelbree stands apart from stimulants is cardiovascular effects. Viloxazine, the active ingredient, has a long safety track record as an antidepressant in Europe going back to 1974, and it was historically noted for carrying a lower risk of cardiotoxicity than older antidepressants.²⁰ Stimulants, by contrast, can raise heart rate and blood pressure, which makes them less suitable for patients with certain cardiac conditions.

Drug Interactions to Know About

Qelbree inhibits a liver enzyme called CYP1A2, which is responsible for breaking down several other drugs and substances. The most practically relevant interaction for many patients is with caffeine. A pharmacokinetic study showed that viloxazine substantially increased the total amount of caffeine circulating in the body, as measured by blood levels over time, even though the peak caffeine concentration did not change much.²¹ In plain terms, your morning coffee will hang around in your system longer if you are taking Qelbree. That can worsen insomnia or jitteriness, which are already common side effects of the drug itself.

The CYP1A2 inhibition also matters for other medications processed by the same enzyme, including certain antipsychotics, the blood thinner warfarin, and theophylline (used for asthma). If you are taking any of these, your prescriber may need to adjust doses.²² This is not unique to Qelbree; other nonstimulant ADHD medications and many antidepressants have their own enzyme-related interaction profiles. But the caffeine interaction is worth highlighting because it affects a substance most adults consume daily, and patients who are not warned about it sometimes attribute worsening insomnia or anxiety to the drug itself when cutting back on coffee would help.

What the Data Say About Breastfeeding

For people who need ADHD treatment while nursing, one of the lingering unknowns until recently was how much viloxazine ends up in breast milk. A pharmacokinetic study in healthy lactating women found that viloxazine partitions into breast milk at a relatively low rate, with a breast-milk-to-plasma ratio of about 0.34. Using standard estimates of infant milk intake, the relative infant dose came out to about 1.5% of the mother’s weight-adjusted dose, which falls well below the commonly used safety threshold of 10%.²³

The women in that study did experience some side effects themselves, most commonly drowsiness (67%), nausea (20%), and dizziness (20%), but these were rated mild and none of the participants dropped out. This is early data from a small study in healthy women rather than women with ADHD taking the drug long-term, so it does not settle the question completely. But it provides the first direct measurement of infant exposure and is likely what clinicians will reference when weighing the risks and benefits for nursing mothers.

Psychiatric Side Effects Beyond Suicidality

The suicidal ideation warning gets the most attention, but Qelbree can produce other psychiatric effects that are worth watching for. The FAERS database analysis flagged anxiety and irritability among the disproportionately reported psychiatric signals.²⁴ The real-world pharmacovigilance comparison with dextroamphetamine found that both drugs shared reports of anxiety, agitation, irritability, and mood swings, though the pattern of which psychiatric effects were most prominent differed between the two drugs.²⁵

In clinical trials these effects were relatively infrequent, and they were not among the top reasons people stopped the drug. But in the real world, psychiatric side effects may be underreported in trials because trial participants are typically screened to exclude significant comorbid mental health conditions. The phase 4 trial that intentionally enrolled adults with coexisting depression or anxiety symptoms found insomnia, somnolence, and decreased appetite leading to discontinuation at noticeable rates, and it was that trial that flagged the three cases of suicidal ideation serious enough to stop treatment.²⁶ The lesson is that patients with pre-existing mood or anxiety disorders may be more susceptible to these effects and deserve closer follow-up.

The Historical Safety Record

Viloxazine is not a new molecule. It was first approved as an antidepressant in the United Kingdom in 1974 and went on to be marketed in several European countries for roughly three decades. During that period, it was used extensively at higher doses than the current ADHD formulation and accumulated a long safety record without any major safety concerns emerging.²⁷ It was eventually withdrawn from the European market for commercial reasons, not safety problems.

That three-decade track record is unusual for a “new” ADHD drug and provides a layer of confidence about rare long-term risks that truly new molecules cannot offer. The extended-release reformulation used in Qelbree changes the absorption pattern but not the molecule itself, so the fundamental safety profile carries over. What the historical use did not test is the pediatric population, since the European formulation was primarily used in adults with depression. The pediatric clinical trials conducted for the FDA approval are still the main source of data for that age group, and long-term extension studies continuing to track growth, tolerability, and psychiatric safety are still ongoing.